CSIMarket
 
Prevail Therapeutics Inc   (PRVL)
Other Ticker:  
 
 

Prevail Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information



PRVL Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) - 29.34 % 8.77 % -2.03 %
Q / Q Revenue Growth (Q3 MRQ) - 17 % 14.33 % 13.28 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) - 13.88 % 4.32 % -3.2 %
Seq. Revenue Growth (for 12 months ending Q3 TTM) - 7.11 % 2.18 % -0.52 %
Revenue 5 Year Average Growth - 3.46 % 8.16 % 10.54 %


PRVL's Growth Comparisons in III. Quarter 2020




Prevail Therapeutics Inc reported top-line of $ 0 millions in the third quarter 2020, compare to $ 0 millions in the same quarter a year ago. Revenues in the Biotechnology & Pharmaceuticals industry grew by 29.34%, while the top-line in the Healthcare sector increased by 8.77%, and overall market declined by -2.03% from the third quarter 2019.

Sequentially company's Revenue were unchanged from the second quarter results. . Looking into annual growth, sales grew by % on average in last five years, while S & P 500's including only Businesses with the third quarter 2020 earnings reports, average yearly sales growth is 10.54%.


Growth Rates of PRVL's Income in the third quarter 2020


PRVL Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 210.89 % -4.7 % -6.93 %
Seq. Operating Income Change (Q3 MRQ) - - 102.69 % 61.86 %
Y / Y Operating Income Growth (Q3 TTM) - 20.99 % 50.87 % -9.34 %
Seq. Operating Income Growth (Q3 TTM) - 35.14 % -1.24 % -3.15 %
Operating Income 5 Year Avg. Change - -10.7 % -1.85 % 12.44 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - 157.92 % 15.82 % -12.84 %
Seq. Income from Cont. Ops. Change (Q3 MRQ) - - 208.29 % 108.36 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - 35.64 % -0.35 % -29.54 %
Seq. Income from Cont. Ops. Change (Q3 TTM) - 29.06 % 4.3 % -3.86 %
Income from Cont. Ops. 5 Year Avg. Change - -8.98 % 3.09 % 10.63 %

PRVL Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - 165.25 % 16.95 % -10.3 %
Q / Q Net Income Growth (Q3 MRQ) - - 247.1 % 113.34 %
Y / Y Net Income Change (Q3 TTM) - 36.92 % -5.59 % -30.13 %
Seq. Net Income Change (Q3 TTM) - 32.13 % 4.77 % -3.08 %
Net Income 5 Year Avg. Growth - -8.97 % 3.38 % 11.57 %

PRVL's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - 189.86 % 15.82 % -12.84 %
Seq. EPS from Cont. Ops. Change (Q3 MRQ) - - 208.29 % 108.36 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Seq. EPS from Cont. Ops. Change (Q3 TTM) - - - 1.84 %
EPS from Cont. Ops. 5 Year Avg. Growth - -34.3 % 3.09 % 10.63 %



PRVL EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - 198.11 % 16.95 % -10.3 %
Q / Q EPS Net Growth (Q3 MRQ) - - 247.1 % 113.34 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - -43.72 %
Seq. EPS Net Change (for 12 months ending Q3 TTM) - - - 1.1 %
EPS Net 5 Year Avg. Change - -8.97 % 3.38 % 11.57 %



Prevail Therapeutics Inc reported bottom-line of $ -0.55 in the third quarter, compare to $ -0.62 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry grew by 198.11%, while Healthcare sector increased by 16.95%, and overall market declined by -10.3%.

Sequentially company's EPS were unchanged from the second quarter results. . Looking into annual growth, income per share grew by % on average in the last five years, while the S & P 500's including only the businesses with the third quarter 2020 financial results, average yearly income per share growth is 11.57%.

PRVL Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 24.44 % 4.37 % -36.86 %
Seq. Free Cash Flow Change (Q3 MRQ) - 44.77 % -4.34 % -38.08 %
Y / Y Free Cash Flow Change (Q3 TTM) - 6.83 % 12.59 % -6.79 %
Seq. Free Cash Flow Change (Q3 TTM) - 5.42 % 1.8 % -7.65 %
Free Cash Flow 5 Year Avg. Change - -2.72 % 5.73 % 14.32 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - -39.78 % -26.09 % -
Seq. Net Cash Flow Change (Q3 MRQ) - - 345.72 % -
Y / Y Net Cash Flow Change (Q3 TTM) - - 64.99 % -
Seq. Net Cash Flow Change (Q3 TTM) - - -5.42 % -7.66 %
Net Cash Flow 5 Year Avg. Change - - 66.57 % 329.87 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -66.8 % 7.89 % 3.85 % -16.87 %
Seq. Capital Expenditures Change (Q3 MRQ) 95.4 % 5.9 % 25.09 % 0.59 %
Y / Y Capital Expenditures Change (Q3 TTM) -69.27 % -55.56 % -10.05 % -15.27 %
Seq. Capital Expenditures Change (Q3 TTM) -35.19 % -2.21 % 1.51 % -4.51 %
Capital Expenditures 5 Year Avg. Change -